Corestemchemon

Focus: Corestemchemon is a South Korean stem cell therapy biotech focused on allogeneic cell therapies for neurological and autoimmune diseases. The company operates as a pre-revenue clinical-stage developer with a concentrated pipeline in ALS and related indications.

Cell Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Corestemchemon

AI assessmentNot Hiring

No open roles listed right now. Follow Corestemchemon to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)

Multiple System Atrophy

N/A

Clinical Trials (1)

NCT04495582Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)

N/A

Help build intelligence for Corestemchemon

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge stem cell manufacturing and allogeneic cell therapy platform with multiple Phase 1-3 programs in CNS diseases
Opportunity to contribute to emerging cell therapy space with high unmet need in ALS, lupus nephritis, and MSA
Early-stage company structure allows hands-on impact on clinical development and regulatory strategy

Watch Out For

Zero current hiring—no active job openings listed, suggesting minimal near-term recruitment or potential cash constraints
Pre-revenue stage with undisclosed funding creates uncertainty around runway and long-term financial stability
Limited public profile, patent data, and publications make external validation of platform strength difficult

Generated by Claude from Corestemchemon's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject with Lupus Nephritis

Lupus Nephritis

N/A

Clinical Trials (1)

NCT04522505Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject with Lupus Nephritis

N/A

Lenzumestrocel

Amyotrophic Lateral Sclerosis

Phase 1

Clinical Trials (1)

NCT06676423Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS

Phase 1

HYNR-CS-Allo

Amyotrophic Lateral Sclerosis

Phase 1

Clinical Trials (1)

NCT01758510Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis

Phase 1

HYNRCS-Allo inj

Amyotrophic Lateral Sclerosis

Phase 1

Clinical Trials (1)

NCT03214146Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS

Phase 1

allogenic bone marrow derived mesenchymal stem cells

Lupus Nephritis

Phase 1

Clinical Trials (1)

NCT03174587Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis

Phase 1

CS10BR05

Multiple System Atrophy

Phase 1

Clinical Trials (1)

NCT03265444Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy